undamentalytics Newsletter
Sign in

Orchestra Biomed Holdings, Inc. revenue

Orchestra Biomed Holdings, Inc.'s revenue was $33.5m in fiscal 2025, up 1169.2% on the year before. Since fiscal 2022 ($3.5m) it has grown at a compound 111.6% a year. Over the last twelve months it was $32.0m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue4333332
Growth on the year before—−21.9%−4.4%+>999%—
Gross profit3323332

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Partnership Revenue $32.9M 98.2% ▲ 1539.5%
Products $611,000 1.8% ▼ 3.5%

From Orchestra Biomed Holdings, Inc.'s 10-K filed March 12, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Health Care Equipment: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Orchestra Biomed Holdings, Inc. $32.0m 986.1% 94.5%
Precision Optics Corporation, Inc. $31.5m 65.2% 14.4%
Retractable Technologies Inc $33.9m -11.2% -14.7%
Stereotaxis, Inc. $30.1m -5.5% 0.8%
Utah Medical Products Inc $36.1m -7.0% -11.4%
Electrocore, Inc. $37.0m 33.5% 50.4%

Compare with peers

Head to head: OBIO vs POCIOBIO vs RVPOBIO vs STXS

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Orchestra Biomed Holdings, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Orchestra Biomed Holdings, Inc.